Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 10/20 | 0.90 |
| ▸ | HRH2 | P25021 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.52 |
| ▸ | ATP4A | P20648 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | ATP4B | P51164 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10425788 | 0.96 | ACHE (0.83) | ACHEHRH2MEN1SLC22A1ABCB11 | |
| SCHEMBL10426667 | 0.96 | ACHE (0.83) | ACHEHRH2MEN1SLC22A1ABCB11 | |
| Nizatidine SCHEMBL13575816 | 0.95 | ACHE (1.00) | ACHEHRH2MEN1SLC22A1ABCB11 | |
| Nizatidine SCHEMBL770 | 0.95 | ACHE (1.00) | ACHEHRH2MEN1SLC22A1ABCB11 | |
| Nizatidine SCHEMBL769 | 0.95 | ACHE (1.00) | ACHEHRH2MEN1SLC22A1ABCB11 | |
| Nizatidine SCHEMBL9241933 | 0.95 | ACHE (1.00) | ACHEHRH2MEN1SLC22A1ABCB11 | |
| SCHEMBL10970986 | 0.94 | ACHE (0.80) | ACHEHRH2MEN1SLC22A1ABCB11 | |
| Nizatidine SCHEMBL5041217 | 0.94 | ACHE (0.98) | ACHEHRH2MEN1SLC22A1ABCB11 | |
| Nizatidine SCHEMBL28723397 | 0.94 | ACHE (0.98) | ACHEHRH2MEN1SLC22A1ABCB11 | |
| SCHEMBL10967376 | 0.93 | ACHE (0.79) | ACHEHRH2MEN1SLC22A1ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0704214-B1 | Process for obtaining pure nizatidine | LILLY CO ELI (US) | 2000-04-26 | — | — | EP | claimed |
| EP-0704214-A1 | Process for obtaining pure nizatidine | ELI LILLY AND COMPANY (US) | 1996-04-03 | — | — | EP | claimed |
| US-5470865-A | Nizatidine | ELI LILLY AND COMPANY (US) | 1995-11-28 | — | — | US | claimed |
| US-20090275622-A1 | NIZATIDINE FORMULATIONS | DR. REDDY'S LABORATORIES LIMITED (IN) | 2009-11-05 | — | — | US | disclosed |
| EP-0704214-B1 | Process for obtaining pure nizatidine | LILLY CO ELI (US) | 2000-04-26 | — | — | EP | disclosed |
| EP-0704214-A1 | Process for obtaining pure nizatidine | ELI LILLY AND COMPANY (US) | 1996-04-03 | — | — | EP | disclosed |
| US-5470865-A | Nizatidine | ELI LILLY AND COMPANY (US) | 1995-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275622-A1 | NIZATIDINE FORMULATIONS | SLC30A5, SLC39A11, NNMT | ACHE 1618/4885HRH2 780/4885MEN1 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.